Cargando…

Genomics and Epigenetics of Malignant Mesothelioma

Malignant mesothelioma is an aggressive and lethal asbestos-related disease. Diagnosis of malignant mesothelioma is particularly challenging and is further complicated by the lack of disease subtype-specific markers. As a result, it is especially difficult to distinguish malignant mesothelioma from...

Descripción completa

Detalles Bibliográficos
Autores principales: Sage, Adam P., Martinez, Victor D., Minatel, Brenda C., Pewarchuk, Michelle E., Marshall, Erin A., MacAulay, Gavin M., Hubaux, Roland, Pearson, Dustin D., Goodarzi, Aaron A., Dellaire, Graham, Lam, Wan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163664/
https://www.ncbi.nlm.nih.gov/pubmed/30060501
http://dx.doi.org/10.3390/ht7030020
_version_ 1783359415663984640
author Sage, Adam P.
Martinez, Victor D.
Minatel, Brenda C.
Pewarchuk, Michelle E.
Marshall, Erin A.
MacAulay, Gavin M.
Hubaux, Roland
Pearson, Dustin D.
Goodarzi, Aaron A.
Dellaire, Graham
Lam, Wan L.
author_facet Sage, Adam P.
Martinez, Victor D.
Minatel, Brenda C.
Pewarchuk, Michelle E.
Marshall, Erin A.
MacAulay, Gavin M.
Hubaux, Roland
Pearson, Dustin D.
Goodarzi, Aaron A.
Dellaire, Graham
Lam, Wan L.
author_sort Sage, Adam P.
collection PubMed
description Malignant mesothelioma is an aggressive and lethal asbestos-related disease. Diagnosis of malignant mesothelioma is particularly challenging and is further complicated by the lack of disease subtype-specific markers. As a result, it is especially difficult to distinguish malignant mesothelioma from benign reactive mesothelial proliferations or reactive fibrosis. Additionally, mesothelioma diagnoses can be confounded by other anatomically related tumors that can invade the pleural or peritoneal cavities, collectively resulting in delayed diagnoses and greatly affecting patient management. High-throughput analyses have uncovered key genomic and epigenomic alterations driving malignant mesothelioma. These molecular features have the potential to better our understanding of malignant mesothelioma biology as well as to improve disease diagnosis and patient prognosis. Genomic approaches have been instrumental in identifying molecular events frequently occurring in mesothelioma. As such, we review the discoveries made using high-throughput technologies, including novel insights obtained from the analysis of the non-coding transcriptome, and the clinical potential of these genetic and epigenetic findings in mesothelioma. Furthermore, we aim to highlight the potential of these technologies in the future clinical applications of the novel molecular features in malignant mesothelioma.
format Online
Article
Text
id pubmed-6163664
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61636642018-10-11 Genomics and Epigenetics of Malignant Mesothelioma Sage, Adam P. Martinez, Victor D. Minatel, Brenda C. Pewarchuk, Michelle E. Marshall, Erin A. MacAulay, Gavin M. Hubaux, Roland Pearson, Dustin D. Goodarzi, Aaron A. Dellaire, Graham Lam, Wan L. High Throughput Review Malignant mesothelioma is an aggressive and lethal asbestos-related disease. Diagnosis of malignant mesothelioma is particularly challenging and is further complicated by the lack of disease subtype-specific markers. As a result, it is especially difficult to distinguish malignant mesothelioma from benign reactive mesothelial proliferations or reactive fibrosis. Additionally, mesothelioma diagnoses can be confounded by other anatomically related tumors that can invade the pleural or peritoneal cavities, collectively resulting in delayed diagnoses and greatly affecting patient management. High-throughput analyses have uncovered key genomic and epigenomic alterations driving malignant mesothelioma. These molecular features have the potential to better our understanding of malignant mesothelioma biology as well as to improve disease diagnosis and patient prognosis. Genomic approaches have been instrumental in identifying molecular events frequently occurring in mesothelioma. As such, we review the discoveries made using high-throughput technologies, including novel insights obtained from the analysis of the non-coding transcriptome, and the clinical potential of these genetic and epigenetic findings in mesothelioma. Furthermore, we aim to highlight the potential of these technologies in the future clinical applications of the novel molecular features in malignant mesothelioma. MDPI 2018-07-27 /pmc/articles/PMC6163664/ /pubmed/30060501 http://dx.doi.org/10.3390/ht7030020 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sage, Adam P.
Martinez, Victor D.
Minatel, Brenda C.
Pewarchuk, Michelle E.
Marshall, Erin A.
MacAulay, Gavin M.
Hubaux, Roland
Pearson, Dustin D.
Goodarzi, Aaron A.
Dellaire, Graham
Lam, Wan L.
Genomics and Epigenetics of Malignant Mesothelioma
title Genomics and Epigenetics of Malignant Mesothelioma
title_full Genomics and Epigenetics of Malignant Mesothelioma
title_fullStr Genomics and Epigenetics of Malignant Mesothelioma
title_full_unstemmed Genomics and Epigenetics of Malignant Mesothelioma
title_short Genomics and Epigenetics of Malignant Mesothelioma
title_sort genomics and epigenetics of malignant mesothelioma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163664/
https://www.ncbi.nlm.nih.gov/pubmed/30060501
http://dx.doi.org/10.3390/ht7030020
work_keys_str_mv AT sageadamp genomicsandepigeneticsofmalignantmesothelioma
AT martinezvictord genomicsandepigeneticsofmalignantmesothelioma
AT minatelbrendac genomicsandepigeneticsofmalignantmesothelioma
AT pewarchukmichellee genomicsandepigeneticsofmalignantmesothelioma
AT marshallerina genomicsandepigeneticsofmalignantmesothelioma
AT macaulaygavinm genomicsandepigeneticsofmalignantmesothelioma
AT hubauxroland genomicsandepigeneticsofmalignantmesothelioma
AT pearsondustind genomicsandepigeneticsofmalignantmesothelioma
AT goodarziaarona genomicsandepigeneticsofmalignantmesothelioma
AT dellairegraham genomicsandepigeneticsofmalignantmesothelioma
AT lamwanl genomicsandepigeneticsofmalignantmesothelioma